149 related articles for article (PubMed ID: 25880149)
21. Optimization of heart FailUre medical Treatment after hospital discharge according to left ventricUlaR Ejection fraction: the FUTURE survey.
Cohen Solal A; Leurs I; Assyag P; Beauvais F; Clerson P; Contre C; Thebaut JF; Genoun M;
Arch Cardiovasc Dis; 2012; 105(6-7):355-65. PubMed ID: 22800720
[TBL] [Abstract][Full Text] [Related]
22. Randomized clinical trial of a postdischarge pharmaceutical care program vs regular follow-up in patients with heart failure.
López Cabezas C; Falces Salvador C; Cubí Quadrada D; Arnau Bartés A; Ylla Boré M; Muro Perea N; Homs Peipoch E
Farm Hosp; 2006; 30(6):328-42. PubMed ID: 17298190
[TBL] [Abstract][Full Text] [Related]
23. The effects of medication supply on hospitalizations and health-care costs in patients with chronic heart failure.
Dilokthornsakul P; Chaiyakunapruk N; Nimpitakpong P; Jeanpeerapong N; Sruamsiri R
Value Health; 2012; 15(1 Suppl):S9-14. PubMed ID: 22265074
[TBL] [Abstract][Full Text] [Related]
24. The burden of non-cardiac comorbidities and association with clinical outcomes in an acute heart failure trial - insights from ASCEND-HF.
Bhatt AS; Ambrosy AP; Dunning A; DeVore AD; Butler J; Reed S; Voors A; Starling R; Armstrong PW; Ezekowitz JA; Metra M; Hernandez AF; O'Connor CM; Mentz RJ
Eur J Heart Fail; 2020 Jun; 22(6):1022-1031. PubMed ID: 32212297
[TBL] [Abstract][Full Text] [Related]
25. Long-term trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003: a population study of 5.1 million people.
Jhund PS; Macintyre K; Simpson CR; Lewsey JD; Stewart S; Redpath A; Chalmers JW; Capewell S; McMurray JJ
Circulation; 2009 Feb; 119(4):515-23. PubMed ID: 19153268
[TBL] [Abstract][Full Text] [Related]
26. Incremental cost-effectiveness of guideline-directed medical therapies for heart failure.
Banka G; Heidenreich PA; Fonarow GC
J Am Coll Cardiol; 2013 Apr; 61(13):1440-6. PubMed ID: 23433562
[TBL] [Abstract][Full Text] [Related]
27. Failure of benefit and early hazard of bucindolol for Class IV heart failure.
Anderson JL; Krause-Steinrauf H; Goldman S; Clemson BS; Domanski MJ; Hager WD; Murray DR; Mann DL; Massie BM; McNamara DM; Oren R; Rogers WJ;
J Card Fail; 2003 Aug; 9(4):266-77. PubMed ID: 13680547
[TBL] [Abstract][Full Text] [Related]
28. Comparative associations between angiotensin converting enzyme inhibitors, angiotensin receptor blockers and their combination, and outcomes in patients with heart failure and reduced ejection fraction.
Savarese G; Edner M; Dahlström U; Perrone-Filardi P; Hage C; Cosentino F; Lund LH
Int J Cardiol; 2015 Nov; 199():415-23. PubMed ID: 26247798
[TBL] [Abstract][Full Text] [Related]
29. Heart failure drug utilization patterns for Medicaid patients before and after a heart failure-related hospitalization.
Howard PA; Shireman TI
Congest Heart Fail; 2005; 11(3):124-8. PubMed ID: 15947532
[TBL] [Abstract][Full Text] [Related]
30. Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial.
Gattis WA; O'Connor CM; Gallup DS; Hasselblad V; Gheorghiade M;
J Am Coll Cardiol; 2004 May; 43(9):1534-41. PubMed ID: 15120808
[TBL] [Abstract][Full Text] [Related]
31. Economic implications of extended-release metoprolol succinate for heart failure in the MERIT-HF trial: a US perspective of the MERIT-HF trial.
Caro JJ; Migliaccio-Walle K; O'Brien JA; Nova W; Kim J; Hauch O; Hillson E; Wedel H; Hjalmarson A; Gottlieb S; Deedwania PC; Wikstrand J;
J Card Fail; 2005 Dec; 11(9):647-56. PubMed ID: 16360958
[TBL] [Abstract][Full Text] [Related]
32. Improving outcomes in heart failure in the community: long-term survival benefit of a disease-management program.
Akosah KO; Schaper AM; Haus LM; Mathiason MA; Barnhart SI; McHugh VL
Chest; 2005 Jun; 127(6):2042-8. PubMed ID: 15947318
[TBL] [Abstract][Full Text] [Related]
33. The real-world evidence of heart failure: findings from 41 413 patients of the ARNO database.
Maggioni AP; Orso F; Calabria S; Rossi E; Cinconze E; Baldasseroni S; Martini N;
Eur J Heart Fail; 2016 Apr; 18(4):402-10. PubMed ID: 26754527
[TBL] [Abstract][Full Text] [Related]
34. Is multidisciplinary care of heart failure cost-beneficial when combined with optimal medical care?
Ledwidge M; Barry M; Cahill J; Ryan E; Maurer B; Ryder M; Travers B; Timmons L; McDonald K
Eur J Heart Fail; 2003 Jun; 5(3):381-9. PubMed ID: 12798838
[TBL] [Abstract][Full Text] [Related]
35. Risk-treatment mismatch in the pharmacotherapy of heart failure.
Lee DS; Tu JV; Juurlink DN; Alter DA; Ko DT; Austin PC; Chong A; Stukel TA; Levy D; Laupacis A
JAMA; 2005 Sep; 294(10):1240-7. PubMed ID: 16160132
[TBL] [Abstract][Full Text] [Related]
36. Predictors of mortality after discharge in patients hospitalized with heart failure: an analysis from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF).
O'Connor CM; Abraham WT; Albert NM; Clare R; Gattis Stough W; Gheorghiade M; Greenberg BH; Yancy CW; Young JB; Fonarow GC
Am Heart J; 2008 Oct; 156(4):662-73. PubMed ID: 18926148
[TBL] [Abstract][Full Text] [Related]
37. Socioeconomic status, Medicaid coverage, clinical comorbidity, and rehospitalization or death after an incident heart failure hospitalization: Atherosclerosis Risk in Communities cohort (1987 to 2004).
Foraker RE; Rose KM; Suchindran CM; Chang PP; McNeill AM; Rosamond WD
Circ Heart Fail; 2011 May; 4(3):308-16. PubMed ID: 21430286
[TBL] [Abstract][Full Text] [Related]
38. Long-term trends of angiotensin-converting enzyme inhibitor and angiotensin-receptor blocker use after heart failure hospitalization in community-dwelling seniors.
Setoguchi S; Levin R; Winkelmayer WC
Int J Cardiol; 2008 Apr; 125(2):172-7. PubMed ID: 17997175
[TBL] [Abstract][Full Text] [Related]
39. Use of valsartan for the treatment of heart-failure patients not receiving ACE inhibitors: a budget impact analysis.
Smith DG; Cerulli A; Frech FH
Clin Ther; 2005 Jun; 27(6):951-9. PubMed ID: 16117995
[TBL] [Abstract][Full Text] [Related]
40. Mineralocorticoid receptor antagonists and cardiovascular mortality in patients with atrial fibrillation and left ventricular dysfunction: insights from the Atrial Fibrillation and Congestive Heart Failure Trial.
O'Meara E; Khairy P; Blanchet MC; de Denus S; Pedersen OD; Levesque S; Talajic M; Ducharme A; White M; Racine N; Rouleau JL; Tardif JC; Roy D;
Circ Heart Fail; 2012 Sep; 5(5):586-93. PubMed ID: 22798522
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
